A Phase 2 interventional study of Dupilumab in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 26 sites in 6 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-11-27.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 25th largest by enrollment, is one of 4 that started in 2015, is one of 7 in phase 2, and was the 12th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is close to the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 19th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2015, is one of 8 in phase 2, and was the 13th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to \<18 years of age) or severe AD (for children ≥6 to \<12 years of age).
The secondary objective of the study is to explore the immunogenicity and efficacy of dupilumab in pediatric patients with moderate-to-severe AD (for adolescents ≥12 to \<18 years of age) or severe AD (for children ≥6 to \<12 years of age).
Key Inclusion Criteria:
Minimum disease severity, as defined by Investigator's Global Assessment (IGA)
Key Exclusion Criteria:
History of any of the following infections:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 will receive dupilumab dosing regimen 1
Drug: Dupilumab
Cohort 2 will receive dupilumab dosing regimen 2
Drug: Dupilumab
Also known as: REGN668(SAR231893)
Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration
Peak dupilumab concentration in serum following single dose administration. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.
Time frame: Day 2, 4, 8, 15, 22, 29, 36, 43, and 50
PK of Dupilumab: Area Under the Plasma Concentration Versus Time Curve (AUClast) After Single Administration
Mean AUC estimates were calculated using mean concentration data at each time point, using a non-compartmental approach (NCA). Calculated AUClast (computed from time zero to the time of the last positive concentration) are presented. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.
Time frame: Day 2, 4, 8, 15, 22, 29, 36, 43, and 50
PK of Dupilumab: Trough Dupilumab Concentration in Serum (Ctrough) Before 3rd and 4th Repeated Dose
Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of study drug.
Time frame: Pre-dose on Day 71 and Day 85
Percent Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD. Analysis was performed on safety analysis set (SAF) that included all subjects who received any study drug. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by last observation carried forward (LOCF).
Time frame: Baseline to Week 12 (one week after last dose)
Percent Reduction From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 12
SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis ("Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis". Dermatology (Basel) 186 (1): 23-31. 1993). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 \[absent disease\] to 103 \[severe disease\]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.
Time frame: Baseline to Week 12 (one week after last dose)
Percent Reduction From Baseline in Pruritus Numerical Rating Scale (NRS) at Week 12
Pruritus NRS scale is an assessment tool that is used to report the intensity of subject's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Subjects were asked the following question: how would a subject rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.
Time frame: Baseline to Week 12 (one week after last dose)
Percentage of Subjects With Investigator Global Assessment (IGA) Score of "0" or "1" (Clear or Almost Clear) at Week 12
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Analysis was performed on SAF. Subjects with rescue treatment usage during the Part B period were specified as non-responders from the time the rescue was used.
Time frame: Week 12
Percent Reduction From Baseline in Body Surface Area (BSA) at Week 12
Body surface area affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Analysis was performed on SAF.
Time frame: Baseline to Week 12
The study was conducted at 25 sites in 6 countries. A total of 88 participants were screened, and of those, 78 participants were randomized with 77 being treated. Ten participants were screen failures as 5 were due to exclusion criteria met \& inclusion criteria not met, 4 participants withdrew consent and 1 participant was lost to follow-up.
| Milestone | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| Started | 20 | 18 | 20 | 19 |
| Treated | 20 | 18 | 20 | 19 |
| Completed | 20 | 18 | 20 | 19 |
| Not completed | 0 | 0 | 0 | 0 |
Peak dupilumab concentration in serum following single dose administration. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.
| mg/L | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration | 9.91 ± 2.15 | 14.3 ± 5.9 | 23.1 ± 8.71 | 32.4 ± 7.04 |
Mean AUC estimates were calculated using mean concentration data at each time point, using a non-compartmental approach (NCA). Calculated AUClast (computed from time zero to the time of the last positive concentration) are presented. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.
| Day*mg/L | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| PK of Dupilumab: Area Under the Plasma Concentration Versus Time Curve (AUClast) After Single Administration | 104 ± NA | 160 ± NA | 362 ± NA | 330 ± NA |
Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of study drug.
| mg/L | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| Day 71 | 10.4 ± 7.16 | 17.2 ± 8.44 | 32.8 ± 18.9 | 42.1 ± 19.4 |
| Day 85 | 18.5 ± 12.4 | 28 ± 12.9 | 58.8 ± 24.4 | 60.3 ± 36.3 |
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD. Analysis was performed on safety analysis set (SAF) that included all subjects who received any study drug. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by last observation carried forward (LOCF).
| percent change | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| Percent Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12 | -66.4 ± 29.25 | -76.2 ± 25.48 | -69.7 ± 24.48 | -63.4 ± 25.37 |
SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis ("Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis". Dermatology (Basel) 186 (1): 23-31. 1993). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 \[absent disease\] to 103 \[severe disease\]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.
| percent change | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| Percent Reduction From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 12 | -47.7 ± 27.27 | -57.5 ± 23.1 | -43.4 ± 25.38 | -46.9 ± 24.31 |
Pruritus NRS scale is an assessment tool that is used to report the intensity of subject's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Subjects were asked the following question: how would a subject rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.
| Percent change | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| Percent Reduction From Baseline in Pruritus Numerical Rating Scale (NRS) at Week 12 | -30.8 ± 68.35 | -41.6 ± 35.32 | -37.6 ± 34.42 | -39.6 ± 40.88 |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Analysis was performed on SAF. Subjects with rescue treatment usage during the Part B period were specified as non-responders from the time the rescue was used.
| Percentage of subjects | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| Percentage of Subjects With Investigator Global Assessment (IGA) Score of "0" or "1" (Clear or Almost Clear) at Week 12 | 10 | 16.7 | 35 | 21.1 |
Body surface area affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Analysis was performed on SAF.
| Percentage of body surface area | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children |
|---|---|---|---|---|
| Percent Reduction From Baseline in Body Surface Area (BSA) at Week 12 | -61 ± 31.08 | -70 ± 31.93 | -60.4 ± 34.04 | -50 ± 30.8 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dupilumab 2mg/kg: Adolescents | 0/20 (0%) | 1/20 (5%) | 11/20 (55%) |
| Dupilumab 2mg/kg: Children | 0/18 (0%) | 0/18 (0%) | 11/18 (61.1%) |
| Dupilumab 4 mg/kg: Adolescents | 0/20 (0%) | 1/20 (5%) | 16/20 (80%) |
| Dupilumab 4 mg/kg: Children | 0/19 (0%) | 2/19 (10.5%) | 18/19 (94.7%) |
| Event | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4 mg/kg: Adolescents | Dupilumab 4 mg/kg: Children |
|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/20 | 0/18 | 0/20 | 1/19 |
| Arthritis bacterialInfections and infestations | 0/20 | 0/18 | 0/20 | 1/19 |
| Dermatitis infectedInfections and infestations | 1/20 | 0/18 | 1/20 | 1/19 |
| PalpitationsCardiac disorders | 1/20 | 0/18 | 0/20 | 0/19 |
| Staphylococcal skin infectionInfections and infestations | 0/20 | 0/18 | 1/20 | 0/19 |
| Event | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4 mg/kg: Adolescents | Dupilumab 4 mg/kg: Children |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/20 | 5/18 | 8/20 | 10/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/20 | 1/18 | 1/20 | 7/19 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 2/20 | 5/18 | 3/20 | 5/19 |
| Abdominal pain upperGastrointestinal disorders | 0/20 | 0/18 | 2/20 | 3/19 |
| NauseaGastrointestinal disorders | 0/20 | 0/18 | 0/20 | 2/19 |
| PyrexiaGeneral disorders | 2/20 | 0/18 | 0/20 | 2/19 |
| Dermatitis infectedInfections and infestations | 0/20 | 1/18 | 2/20 | 2/19 |
| RhinitisInfections and infestations | 0/20 | 1/18 | 0/20 | 2/19 |
| DizzinessNervous system disorders | 0/20 | 0/18 | 0/20 | 2/19 |
| HeadacheNervous system disorders | 1/20 | 1/18 | 1/20 | 2/19 |
| Age, Continuous(years) | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children | Total |
|---|---|---|---|---|---|
| Mean | 14.7 ± 2.01 | 8.2 ± 1.62 | 14.3 ± 1.66 | 8.2 ± 1.99 | 11.5 ± 3.64 |
| Sex: Female, Male(Participants) | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children | Total |
|---|---|---|---|---|---|
| Female | 11 | 9 | 11 | 8 | 39 |
| Male | 9 | 9 | 9 | 11 | 38 |
| Ethnicity(Participants) | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 20 | 18 | 20 | 18 | 76 |
| Race(Participants) | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children | Total |
|---|---|---|---|---|---|
| White | 17 | 17 | 15 | 18 | 67 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| Asian | 2 | 0 | 3 | 0 | 5 |
| Other | 1 | 1 | 1 | 0 | 3 |
| Number of Subjects with Investigator Global Assessment (IGA) score of 3 or 4(Participants) | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children | Total |
|---|---|---|---|---|---|
| IGA score of 3 | 8 | 1 | 11 | 0 | 20 |
| IGA score of 4 | 12 | 17 | 9 | 19 | 57 |
| Eczema Area and Severity Index (EASI) score(Score on a scale) | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children | Total |
|---|---|---|---|---|---|
| Mean | 34.8 ± 17 | 32.9 ± 15.53 | 28.6 ± 14.7 | 38.8 ± 18.64 | 33.7 ± 16.62 |
| Pruritus Numerical Rating Scale (NRS)(Score on a scale) | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children | Total |
|---|---|---|---|---|---|
| Mean | 6.1 ± 2.47 | 6.4 ± 2.23 | 6.9 ± 2.21 | 6.7 ± 2.35 | 6.5 ± 2.29 |
| Body Surface Area (BSA) Involvement with Atopic Dermatitis (AD)(Percentage of body surface area) | Dupilumab 2mg/kg: Adolescents | Dupilumab 2mg/kg: Children | Dupilumab 4mg/kg: Adolescents | Dupilumab 4mg/kg: Children | Total |
|---|---|---|---|---|---|
| Mean | 52.2 ± 24.78 | 59 ± 22.49 | 45.9 ± 25.34 | 62.3 ± 30.34 | 54.6 ± 26.19 |
1 further baseline measures are reported on the registry.
Ran from Mar 2015 to primary completion in Mar 2016, 12 months.
Results were first posted in Oct 2020, 4 years 6 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab